Drug Trial Radar · NCT07333352
Phase II Clinical Trial of PCV24 in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
480
Actual
Start
Sep 11, 2025
Primary completion
Apr 14, 2026
Study completion Apr 14, 2026
Sponsor
- Lead sponsor
- Reinovax Biologics Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Jan 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 weeks, up to 71 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months. The purpose of this study is to evaluate the immunogenicity and safety of the 24-valent pneumococcal polysaccharide conjugate vaccine.
Conditions
- Pneumococcal Infectious Disease
Interventions
24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700)Biological
24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700) consisting of polysaccahrides from 24 pneumococcal serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F conjugated two carrier proteins. Each dose contains 0.5 ml vaccine in a prefilled syringe.
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)Biological
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13) consisting of plosaccharides from 13 pneumococcal serotypes: 1, , 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F conjugated CRM197. Each dose contains 0.5 ml vaccine in a prefilled syringe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with the pneumococcal serotype-specific IgG antibody concentration ≥0.35 μg/ml.Time frame: 30 days post the primary and booster immunization.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Luzhou District Center for Disease Control and Prevention
Changzhi, Shanxi, China
Qinxian County Center for Disease Control and Prevention
Changzhi, Shanxi, China
Kuangqu District Center for Disease Control and Prevention of Yangquan City
Yangquan, Shanxi, China
Xinjiang County Center for Disease Control and Prevention
Yuncheng, Shanxi, China
Jishan County Center for Disease Control and Prevention
Yuncheng, Shanxi, China
Yongji City Center for Disease Control and Prevention
Yuncheng, Shanxi, China
Shangdang District Center for Disease Control and Prevention of Changzhi City
Yuncheng, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.